YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Why the AvenCell financing matters for Ligand Pharmaceuticals Ligand Pharmaceuticals (LGND) has agreed to provide up to $47 million in funding to AvenCell Therapeutics, tying most of the capital to clinical milestones in AvenCell's CAR-T t…
Ligand Pharmaceuticals has delivered a very strong run in recent years, and the question now is whether the cash the business can generate is enough to support where the stock trades today. With a Discounted Cash Flow (DCF) view available,…
Ligand Pharmaceuticals recently entered a US$47 million financing agreement with AvenCell Therapeutics, including up to US$6 million in Series C funding and as much as US$41 million tied to clinical milestones for AvenCell's CAR-T therapy…
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is building a business model that differs from that of many drug developers. Rather than relying on internally operated drug development programs, the company funds third-party programs and…
[Wall Street sign in Lower Manhattan, NYC] georgeclerk * Barclays initiated Ligand Pharmaceuticals (LGND [https://seekingalpha.com/symbol/LGND]) with an Outperform rating, saying that the company's transition to loyalty aggregation has the…
Ligand Pharmaceuticals JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage c…
$23 million upfront payment immediately monetizes future royalties associated with Ryjunea in Europe, the Middle East, and Africa Capital further strengthens Sydnexis' balance sheet as Company continues to advance SYD-101 through U.S. regu…
SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by new investor Signet Healthcare Partners ("…
Ligand Pharmaceuticals Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients Ligand will receive a tiered low-double-digit to high-teens royal…
Is it better to own a company already selling drugs or one with a potential blockbuster in testing? Investors are weighing Axsome Therapeutics (NASDAQ:AXSM) against Viking Therapeutics (NASDAQ:VKTX) to decide. Axsome focuses on commerciali…
On August 6, Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results showing royalty revenue up 32% year over year, just weeks after the company closed its acquisition of XOMA Royalty. Total revenue reached $63.7 million…
Key Points Interested in Ligand Pharmaceuticals Incorporated? Here are five stocks we like better. XOMA acquisition doubled Ligand's portfolio to more than 220 partnered programs, adding seven commercial-stage assets, 14 late-stage program…
Ligand Pharmaceuticals JUPITER, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced its senior management team will participate in the following upcoming investor conferences: Wells Fa…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ligand Pharmaceuticals stock has surged over the past five years, yet the valuation signals are split, with a Discounted Cas…
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Ligand Pharmaceuticals (LGND) is back in focus after its recent second quarter report and reaffirmed 2026 guidance. The company pos…
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Head of Investor Relations - Melanie HermanChief Executive Officer - Todd DavisChief Financial Officer - Octavio EspinozaVice President of Portfol…
On the IBD 50 and the latest list of new buys by top funds, Ligand stock targets a breakout but faces this test first. Continue Reading
Orchestra BioMed Holdings, Inc. The BACKBEAT global pivotal trial ("BACKBEAT Trial"), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data pres…
By John Vandermosten, CFA NASDAQ: LGND READ THE FULL LGND RESEARCH NOTE Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported second quarter 2026 results boasting total revenue and income of $63.7 million, a 34% year over year increase. Adj…
This article first appeared on GuruFocus. Total Revenue: $64 million, up 34% year over year. Royalty Revenue: $48 million, up 32% year over year, driven by strength from Filspari, Otuber, and Zilsubme. Adjusted Diluted EPS: $2.37, up 48% y…
Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary - Moby Strategic Transformation and Portfolio Scaling Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show yo…
Ligand stock landed in a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike. Continue Reading
Ligand stock bounded out of a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike. Continue Reading
Ligand stock slipped early Thursday after the royalty powerhouse reported better-than-expected earnings and sales. Continue Reading
Ligand Pharmaceuticals Second quarter performance driven by strong year-over-year royalty revenue growth of 32% Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged Conference call begins at 8:30 a.m. Eastern Time today…
LGND stock has risen more than 56.5% so far in 2026. Ligand doesn't make drugs; it forks over funding in exchange for Big Pharma royalties. Continue Reading
Ligand Pharmaceuticals JUPITER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026. The company w…
[crash in the market at wall street] franckreporter * Citi has resumed its coverage of Ligand Pharmaceuticals (LGND [https://seekingalpha.com/symbol/LGND]) with a buy rating saying that its acquisition of XOMA Royalty adds a significant nu…
Quick Read Futures traded higher Tuesday after all four major indices fell Monday, with Iran's foreign ministry signaling openness to further discussions. ADBE was slashed to Underweight at a $240 target, while Morgan Stanley crashed CRM's…
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Ligand Pharmaceuticals stock has delivered a very large 338.7% return over the past three years, yet its valuation signals are spli…
Shares of Agenus AGEN soared nearly 83% on Monday after the biotech announced an oversubscribed private placement of up to $340 million. The financing enables the company to pursue its strategic pivot toward a registrational phase III stud…
XOMA Royalty Corporation EMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has completed its previously announced acquisition of XOMA Roya…
Ligand Pharmaceuticals Acquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), andmore than 100 development and commercial-stage assets, creating long-term opportu…
Agenus AGEN shares soared 82.7% in the last trading session to close at $6.12. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 1.5% gain over the past four week…
Agenus shares surge as company secures up to $340M to advance colon cancer trial Proactive uses images sourced from Shutterstock Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company announced…
Stock chart with green arrow moving up ©Adobe Stock Images Private Placement Strengthens Funding Position Agenus Inc. (NASDAQ:AGEN) shares climbed 13% in premarket trading on Monday after the biotechnology company announced an $85 million…